Skip to main content

DYWIDAG Group – DSI Holding GmbH has successfully priced a subsequent bond issuance and initiates written procedure under its existing bonds

Priced issuance of EUR 50 million subsequent bond issue to partly finance the acquisition of Interspan (Holdings) Pty Limited Munich, Gerrmany, June 12, 2026 (GLOBE NEWSWIRE) — DSI Holding GmbH (the “Issuer“), part of DYWIDAG Group (“DYWIDAG“), has today announced the entering into a definitive agreement to acquire Interspan (Holdings) Pty Limited a leading provider of post-tensioning and concrete repair & strengthening services in Australia, UK and Europe (the “Acquisition“). To finance part of the Acquisition, the Company has successfully priced an  issuance of subsequent senior secured bonds in an amount of EUR 50 million (the “Tap Issue“) under the terms and conditions (the “Terms and Conditions“) for the Company’s outstanding up to EUR 150,000,000 senior...

Continue reading

DYWIDAG Group Acquisition of Interspan

A transformative acquisition creating a global market leader Munich, Germany, June 12, 2026 (GLOBE NEWSWIRE) — DYWIDAG Group (“DYWIDAG”), a leading global provider of geotechnical products, post-tensioning services and stay-cable solution services today announces it has entered into a definitive agreement to acquire Interspan (Holdings) Pty Limited (“Interspan”) a leading provider of post-tensioning and concrete repair & strengthening services in Australia, UK and Europe. The transaction is expected to close in July 2026, subject to customary closing conditions (including completion of a written procedure with the company’s bondholders) and any necessary regulatory approvals Founded in 2006 and headquartered in Sydney (Australia), Interspan employs more than 400 people, has annual revenues of 75m euros and long-term relationships...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 11 06 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [ANIMALCARE GROUP PLC – 11 06 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Columbia Financial, Inc. and Northfield Bancorp, Inc. Announce Mailing of Merger Consideration Election Materials and Deadline to Elect Preferred Form of Merger Consideration

FAIR LAWN, N.J. and WOODBRIDGE, N.J., June 11, 2026 (GLOBE NEWSWIRE) — Columbia Financial, Inc. (“Columbia”) (NASDAQ: CLBK), a Delaware corporation and the mid-tier holding company for Columbia Bank (the “Bank”), and Northfield Bancorp, Inc. (“Northfield”) (NASDAQ: NFBK), the holding company for Northfield Bank, jointly announced today that Columbia has provided an election form and letter of transmittal (together with the related instructions, the “Election Materials”) to the holders of Northfield common stock so that Northfield stockholders may elect to receive, upon the completion of the previously announced merger of the Holding Company and Northfield, either (i) shares of common stock of Columbia Financial, Inc., a newly formed Maryland corporation (the “Holding Company”) that will become the holding company for the Bank following...

Continue reading

Vornado Realty Trust Completes Acquisition of 49% Interest in Park Avenue Plaza 

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) announced today that it has completed its previously announced acquisition of a 49% interest in Park Avenue Plaza. The property was acquired at a gross valuation of $1.1 billion ($950 per square foot), a significant discount to replacement cost. Park Avenue Plaza is a 45-story, 1.2 million rentable square foot building located at 55 East 52nd Street. The trophy, Class A office building, co-owned by Fisher Brothers, has protected Park Avenue views and occupies the full through-block between East 52nd and East 53rd Street. The property is located directly across 52nd Street from Vornado’s 350 Park Avenue development. Park Avenue Plaza is 99% occupied by blue-chip tenants with an 11-year weighted-average lease term and substantially below-market rents. Vornado...

Continue reading

Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accretive: expected to support margin expansion, profitability, and cash flow. Deepens vertical integration: expected to drive synergies, optimized production, economies of scale, expanded capacity, and a strengthened R&D engine. State-of-the-art production plant: GMP-licensed, approximately 59,000 square feet, built to the highest European standards, providing a clear growth avenue. Manufacturing excellence: a broad range of dosage forms, certified to GMP, ISO, Kosher, and Halal standards, with site registrations for the UAE, Qatar, Iraq and Lebanon. Boosts product portfolio: adds advanced and branded generics and OTC pharmaceutical products...

Continue reading

OVH Groupe enters into exclusive negotiations to acquire Gladia, expert in voice AI

Roubaix – June 11th, 2026 – OVH Groupe, a sovereign, global player and European leader in Cloud and AI, announces that it is entering into exclusive negotiations to acquire Gladia, the expert in AI speech-to-text (STT). This transaction aims to strengthen OVH Groupe’s expertise in multimodal and agentic generative AI.                  GladiaFounded in 2022 in Paris, Gladia is a French AI startup specializing in transcription and audio intelligence. Through a single API, the platform transcribes conversations in real time and in batch across more than 100 languages, turning audio data into structured, actionable information. Gladia today supports more than 300,000 developers and 2,000 enterprise customers, including HeyGen, Livestorm, Attention, Circleback, Method Financial, Recall.ai, and Leexi. Through this acquisition, OVH Groupe...

Continue reading

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

– Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 – Azora’s oral candidate, AT177, is a novel, colon‑targeted AhR agonist rationally engineered to have minimal systemic exposure and designed to mitigate safety concerns with systemically absorbed AhR agonists – $32 million in upfront financing with the potential to receive an additional $32 million under additional milestone tranches – Adial to host a conference call today, June 11, 2026 at 1pm ET GLEN ALLEN, Va. and LOS ANGELES, June 11, 2026 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”),...

Continue reading

Top Aces to Acquire Select Global International, Strengthening Canada’s Sovereign Fighter Pilot Training Capability

Advancing Canadian‑Led Live‑Virtual‑Constructive Training for the RCAFTop Aces to Acquire SGITop Aces today announced an agreement to acquire Select Global International (“SGI”)MONTREAL, June 11, 2026 (GLOBE NEWSWIRE) — Top Aces Inc. (“Top Aces”), a global leader in advanced operational air combat training, today announced an agreement to acquire Select Global International (“SGI”), a Canadian defence company with deep expertise in simulator-based fighter pilot instruction supporting the Royal Canadian Air Force (“RCAF”). Founded in 2013, SGI has built a strong reputation delivering high-fidelity synthetic training solutions for CF-18 aircrew. The company is comprised of highly experienced former CF-18 instructor pilots, many of whom have recent operational and command experience within the RCAF. The acquisition brings...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.